Ham Mehlman

Hamilton Mehlman is a seasoned professional with a strong background in life sciences, biotechnology, corporate management, and strategic consulting.

With a career spanning many leadership roles, Mr. Mehlman's most recent position as CFO at Guardian Therapeutics, Inc. in Lexington, MA showcased his expertise in guiding startups through their initial phases.

As the CEO and Director of Parabase Genomics, he pioneered the use of targeted next-generation DNA sequencing for diagnosing genetic diseases in newborns.

Throughout his career, Mr. Mehlman has made significant contributions to the life sciences industry, including strategic investments in both public and private companies.

His experience includes roles as a Fund Manager, Equity Analyst, and Partner at Essex Investment Management, where he played a key role in growing firm assets substantially.

Additionally, he founded Andesite Inc., a successful long-short life science investment company managing significant funds.

Mr. Mehlman's operational and consulting roles in various life science companies have further solidified his reputation as a strategic thinker and industry expert.

His educational background includes degrees from Harvard Business School, Harvard College, and partial medical education at Tufts University School of Medicine, reflecting his diverse interests and commitment to continuous learning.

Formerly associated with prestigious organizations like Peregrine Partners Network LLC, Boston University, Danforth Advisors, LLC, and more, Mr. Mehlman's leadership and expertise have left a lasting impact on the biotechnology and life sciences landscape.